We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diabetic Kidney Disease and Risk of Incident Stroke Among T2D Adults

By LabMedica International staff writers
Posted on 08 Apr 2022
Print article
Image: The BN II System is an easy-to-use, reliable nephelometric analyzer that offers a broad range of protein assays (Photo courtesy of Siemens Healthineers)
Image: The BN II System is an easy-to-use, reliable nephelometric analyzer that offers a broad range of protein assays (Photo courtesy of Siemens Healthineers)

Atherosclerotic cardiovascular disease (ASCVD) is a significant cause of morbidity and mortality among people with type 2 diabetes (T2D) . The huge burden of ASCVD in T2D, mainly coronary artery disease (CAD) and stroke, constitutes a major public health problem in this population and accounts for significant disability and healthcare costs.

Diabetes mellitus is associated with a 3-fold greater age-adjusted risk of stroke and a higher post-stroke mortality. The increased burden of stroke in individuals with T2D is driven in large part by the high prevalence of the metabolic syndrome components in this population. However, accruing evidence suggest that other factors such as diabetes-related microvascular complications might play a role. Indeed, diabetic retinopathy was found to be associated with higher risk of stroke in people with T2D.

A team of medical scientists collaborating with those at SOVAH Health (Danville, VA, USA) included in their study a total of 9,170 participants; mean age: 62.8 ± 6.6 years, 38.2% women, 62.9% white. Of the entire sample, 62.2% of participants had no chronic kidney disease (CKD); 13.3%, CKD G1; 14.1%, CKD G2; and 10.5%, CKD G3. Urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were assessed at baseline.

Urine microalbumin was assayed on spot urine by immunonephelometry on a BN11 nephelometer (Siemens Healthineers, Erlangen, Germany). Urinary albumin excretion was estimated as the urine albumin-to-creatinine ratio (UACR) in mg albumin/g of creatinine. eGFR was calculated in mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Serum and urine creatinine was measured via enzymatic methods on a Roche Double Modular P Analytics automated analyzer (Roche Diagnostics, Indianapolis, IN , USA).

The scientists reported that over a median follow-up of 4.9 years, 156 participants developed a stroke (incidence rate 3.6/1,000 person-years). After adjusting for relevant confounders, higher UACR and lower eGFR were each associated with increased risk of stroke. Compared to UACR < 30 mg/g, moderate albuminuria and severe albuminuria were associated with increasing hazards for stroke (HR 1.61 and 2.29 respectively). Compared to eGFR of ≥ 60 mL/min/1.73 m2, decreased eGFR (eGFR < 60 mL/min/1.73 m2) was associated with higher risk of stroke (HR 1.50). Compared to no CKD, worsening CKD stage was associated with an increasing risk of stroke (HRs of 1.76 for CKD G1, 1.77 for CKD G2, and 2.03 for CKD G3).

The authors concluded that in a large and diverse cohort of adults with type 2 diabetes, higher UACR, decreased eGFR, and worsening CKD stages were associated with increased risk of stroke, independently of other stroke risk factors. The study was published on March 29, 2022 in the journal BMC Medicine.

Related Links:
SOVAH Health
Siemens Healthineers 
Roche Diagnostics 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.